11:52 AM EST - Oncolytics Biotech Inc. : announced preliminary results from its U.S. Phase 2 clinical trial in patients with squamous cell carcinoma of the lung (SCCLC) using intravenous administration of REOLYSIN® in combination with carboplatin and paclitaxel (REO 021). Oncolytics Biotech Inc.
shares T.ONC are trading up $0.17 at $2.57.
